Midostaurin, the first FDA-approved FLT3 inhibitor, is a first-generation type I FLT3 inhibitor with off-target effects on KIT and was shown to decrease blast percentages in patients with relapsed/refractory AML when used as a single agent regardless of FLT3 mutation status [81]. Here, KIT is linked to acute myeloid leukemia.